CD274 and cancer: ICIs targeting PD-1/PD-L1, including pembrolizumab, nivolumab, atezolizumab, and tiselizumab, has shown potent clinical efficacy for various cancers.[19] Immunotherapy combined with SBRT was shown to produce synergistic effects.